Liana S. Rosenthal

This paper develops PMO-based RNA-degrading chimeras that target SNCA mRNA to reduce α-synuclein levels and prevent pathological aggregation in vitro and in vivo.

The paper identifies distinct α-synuclein strains associated with cognitive decline in Parkinson's disease and shows AI-based analysis of these strains improves clinical stratification.

This paper identifies NOD2/RIPK2 signaling as a key driver of neuroinflammation in Parkinson's disease, showing that pathological α-synuclein activates this pathway in microglia, leading to neurodegeneration and that targeting NOD2 or RIPK2 protects dopamine neurons.

The paper identifies potential biomarkers for progressive supranuclear palsy (PSP) in cerebrospinal fluid using proteomics, finding ATP6AP2 as the top performer in distinguishing PSP from Parkinson's Disease and controls.

This paper performs a large meta-analysis of GWAS in dementia with Lewy bodies, identifying sex-specific genetic risk signals and highlighting the need for larger cohorts.

This paper identifies five new genetic risk loci for Lewy body dementia through whole-genome sequencing and shows shared risk profiles with Alzheimer’s and Parkinson’s disease.

The paper identifies genetic modifiers of risk and age at onset in GBA-associated Parkinson disease and Lewy body dementia using large case-control datasets and genome-wide association studies.

This study estimates the heritability of dementia with Lewy bodies (DLB) and finds it to be higher than previous estimates, with low variance explained by polygenic risk scores from Parkinson's or Alzheimer's disease.